A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

@inproceedings{Chiappori2012API,
  title={A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer},
  author={Alberto Alejandro Chiappori and Marshall T. Schreeder and Mehdi M. Moezi and Joe J. Stephenson and Jennifer L Blakely and Ravi Salgia and Quincy S-C Chu and Helen J. Ross and Deepa Suresh Subramaniam and Judy Schnyder and Mitchell S Berger},
  booktitle={British Journal of Cancer},
  year={2012}
}
Background:Bcl-2 family genes are frequently amplified in small cell lung cancer (SCLC). A phase I trial was conducted to evaluate the safety of obatoclax, a Bcl-2 family inhibitor, given in combination with standard chemotherapy.Methods:Eligible patients (3–6 per cohort) had extensive-stage SCLC, measurable disease, ⩽1 before therapy, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients were treated with escalating doses of obatoclax, either as a… CONTINUE READING
Highly Cited
This paper has 20 citations. REVIEW CITATIONS
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 12 citations